Was ist die Webseite?

Convatec Wound

Startseite
Deutschland
Bremen
Convatec Wound

Kontaktinformationen, Karte und Wegbeschreibungen, Kontaktformulare, Öffnungszeiten, Dienstleistungen, Bewertungen, Fotos, Videos und Ankündigungen von Convatec Wound, Medizin und Gesundheit, Bremen.

At Convatec, is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. .

28/05/2026

Same knees, same hospital, two very different results.

Terry had a successful knee replacement in 2024 with Aquacel Surgical supporting his recovery. In 2025, he had the same procedure on his right knee. Unfortunately, a different dressing was used which caused Terry issues. Due to this change in dressing Terry reported that he lacked trust in the dressing for simple things like walking upstairs or bending his leg.

When post-operative outcomes differ, it’s worth looking at what’s changed.

27/05/2026

85% of diabetes-related amputations occur as a result of diabetic foot ulcers (DFUs)¹. Yet DFUs often remain misunderstood outside clinical settings.

In our first episode of the DFU Spotlight Series, global experts unpack why DFUs are so widespread — affecting an estimated 40–60 million people² — and what makes them particularly challenging due to associated comorbidities.

🎥 Watch the experts explain the scale of DFUs and why early identification matters.

Stay tuned for Episode 2, where we explore the common outcome of infection.

1. Voza FA et al. Fibroblasts in diabetic foot ulcers. Int J Mol Sci. 2024;25(4):2172.

2. Jupiter DC et al. The impact of foot ulceration and amputation on mortality in diabetic patients. I: From ulceration to death, a systematic review. Int Wound J. 2016;13(5):892–903.

AP-79201-GBL-ENG-v1

20/05/2026

Hear from Terry, who, aged 60 had a total left knee replacement in 2024 following an arthritis diagnosis.

Aquacel™ Surgical was applied to the incision, which made him feel comfortable with the dressing and allowed him to fully complete his physio without any stretching, so much so he described it as a “second skin”.

18/05/2026

Debridement may help reduce infection risk and accelerate healing

In a Randomised Controlled Trial on hard‑to‑heal Venous Leg Ulcers, Aquacel® Ag+ Extra™ with Antibiofilm MORE THAN SILVER™ Technology demonstrated superior slough reduction and complete debridement compared with Cutimed® Sorbact®.

Antibiofilm performance united with debridement. See the results.

13/05/2026

💜 Performance You Can Rely On.

At , during our symposium “A Year of Healing”, we discussed what makes ConvaFoam™ unique.¹

The only foam combining three technologies in one dressing:
✔️Hydrofiber
✔️Superabsorber
✔️ConvaTac™

Early NHS data demonstrated that ConvaFoam™ achieved 98% of clinical objectives, significantly reduced dressing changes and decreased overall resource use and spend. ²

During the session, Shauna Roberts, BSc (Hons), Advanced Wound Care Technical Lead, shared the research and development behind ConvaFoam™ innovation. ¹

Read more here: https://brnw.ch/21x2soh

European Wound Management Association - EWMA

References:
¹ Convatec. A Year of Healing: Advancing wound care with a next-generation foam dressing. EWMA 2026 ConvaFoam™ Symposium Programme Information.

² Hughes M, Wilkins J, Fisher J, Rodger R. Early outcomes of implementing a new multilayer foam dressing in an acute setting: assessing clinical and financial impact through value-based procurement. EWMA 2026 Abstract [1196].

AP-79504-GBL-ENG-v1

11/05/2026

Join us at the 21st Malvern Diabetic Foot Conference where we will be hosting a symposium on ConvaNiox™, our multimodal, nitric oxide-generating dressing for diabetic foot ulcers (DFUs).¹

Chaired by Dr Chris A. Manu and joined by Daniel Metcalf our session will begin with an explanation of the multimodal features of ConvaNiox™ that have contributed to the superior healing outcomes compared to standard of care in an RCT.²

A post-hoc analysis will present further data on ulcer duration, concomitant antibiotic usage and infection status, highlighting potential use strategies for ConvaNiox™.

Lastly, we’ll hear about experiences using ConvaNiox™ that show its strength in tackling a range of challenging DFUs.

📍Join us at Malvern on the 14th of May for the full session

🔗 Learn more about ConvaNiox™ here: https://brnw.ch/21x2nSN

References:
1. ConvaNiox Claims Summary, RPT-088112 v2.0. Data on file. Convatec Inc., 2025.

2. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes—ProNOx1 study. Wound Repair Regen. 2018;26:228–237.

AP-79967-GBL-ENG-v1

11/05/2026

What a week at 💜

From inspiring conversations and shared learning to innovation on the stand and moments that reminded us why this community matters, EWMA 2026 was truly energising.

It was a privilege to connect with clinicians, partners, speakers, and innovators from across the wound care community - all united by a shared commitment to improving outcomes for patients worldwide. From insightful discussions at our booth to meaningful exchanges throughout the congress, our team left feeling motivated by the passion, collaboration, and expertise on display.

Thank you to everyone who engaged with us throughout the week and continues to move wound care forward every day. We’re proud to be part of this community and the collective commitment to advancing care together.

Here’s a look back at some of our highlights from EWMA 2026.

European Wound Management Association - EWMA

11/05/2026

At , we hosted a 60-minute session exploring a novel approach to diabetic foot ulcer management.

During the session, we explored the science behind ConvaNiox™, summarised laboratory data on its multimodal features and shared the randomised control trial results showing ConvaNiox™’s superior healing outcomes compared to standard of care dressings.¹

We also heard real-world experiences from clinicians across Europe, alongside data demonstrating the cost-effectiveness of this innovative approach.²

Thank you to our Chair, Prof José Luis Lázaro-Martínez, and faculty Prof Alberto Piaggesi, and Daniel Metcalf for leading such an important discussion.

"We are thrilled to see the patients that have recently benefited from ConvaNiox from Italy and Spain. Presented by world-renowned diabetic foot ulcer experts, these cases build on our randomized controlled trial data, while highlighting the clinical benefits of the multimodal features of ConvaNiox™" - Daniel Metcalf

Read more here: https://brnw.ch/21x2nmF

References:
1. Edmonds ME, et al. Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study. Wound Repair Regen. 2018;26(2):228-237

2. Convatec. A Novel, Multimodal Nitric Oxide-Generating Dressing for Superior Clinical Outcomes in Diabetic Foot Ulcers. EWMA 2026 ConvaNiox™ Symposium Outline.

AP-80022-GBL-ENG-v1 (v1.0)

10/05/2026

In December 2024, eight of the world’s leading DFU (diabetic foot ulcer) experts gathered in London to discuss a better future for DFU care.

Among the key messages of this round table meeting were²:

• How DFUs remain an urgent and highly burdensome aspect of diabetes for patients due to infection, hospitalisation and amputation.

• How DFU treatment is in desperate need of further innovation to curb persistent infections and improve healing outcomes.

• How proactivity in treatment, better education, new patient metrics and simplicity in guidelines alongside novel innovations like ConvaNiox™ could be key to improving future DFU care.

Read the article today to learn more about the discussions shaping the future of DFU care: https://brnw.ch/21x2mvS

References:

1. This article is based on the first roundtable meeting, part of a wider multi-stage dialogue, of leading global experts in DFU care.

2. Armstrong DG, et al. Global expert dialogue on diabetic foot ulcer care: driving urgency, innovation, and collaboration. J Wound Manage. 2026;27(1):105-108.

*All authors serve as consultants to Convatec.

AP-79742-GBL-ENG-v1

07/05/2026

At , Convatec is showcasing the breadth, depth and momentum behind our strongest-ever Advanced Wound Care innovation pipeline.

Tanja Dormels, President of Advanced Wound Care, joined us on site, reinforcing why this moment matters and how evidence‑led innovation, patient‑centred design, and 30 years of Hydrofiber® technology are coming together to meaningfully advance healing and reshape clinical practice.

From next‑generation foam and nitric oxide‑generating dressings to Wound Hygiene and new clinical and real‑world evidence across hard‑to‑heal wounds, EWMA is an important moment to demonstrate how Convatec is leading the industry to meet the needs of patients and healthcare professionals worldwide.

Explore the insights and come visit us at booth F10 to continue the conversation at European Wound Management Association - EWMA

Adresse

Bremen
28307

Webseite

https://www.convatec.com/en-gb/wound-skin/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Convatec Wound erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.